Exercise and cancer
Idorn, Manja; thor Straten, Eivind Per

Published in:
Cancer Immunology, Immunotherapy

DOI:
10.1007/s00262-017-1985-z

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Idorn, M., & thor Straten, P. (2017). Exercise and cancer: from “healthy” to “therapeutic”? DOI: 10.1007/s00262-017-1985-z
Exercise and cancer: from “healthy” to “therapeutic”? 

Manja Idorn1 · Per thor Straten1,2

Received: 26 July 2016 / Accepted: 5 March 2017 / Published online: 21 March 2017
© The Author(s) 2017. This article is an open access publication

Abstract Exercise improves functional capacity and patient-reported outcomes across a range of cancer diagnoses. The mechanisms behind this protection have been largely unknown, but exercise-mediated changes in body composition, sex hormone levels, systemic inflammation, and immune cell function have been suggested to play a role. We recently demonstrated that voluntary exercise leads to an influx of immune cells in tumors, and a more than 60% reduction in tumor incidence and growth across several mouse models. Given the common mechanisms of immune cell mobilization in mouse and man during exercise, we hypothesize that this link between exercise and the immune system can be exploited in cancer therapy in particular in combination with immunotherapy. Thus, we believe that exercise may not just be “healthy” but may in fact be therapeutic.

Keywords Exercise · NK cells · Immune cell mobilization · Tumor infiltration · Combination treatment · CIMT 2016

Physical exercise has documented impact on health and well-being of humans, and is associated with a reduced risk of mortality [1]. Exercise has also been shown to have a preventive effect on the risk of cancer, i.e., leisure-time exercise is associated with a lower cancer incidence. Although epidemiological studies of exercise and its impact on slowly developing diseases are often self-reported and might be biased by other lifestyle factors and often, available data strongly suggest exercise to be preventive for cancer [2, 3]. Concerning a potential role for exercise in cancer prognosis and therapy, physical activity has been reported to be associated with a lowered risk of disease recurrence (breast cancer and colorectal cancer) [3, 4]. However, data are needed in other cancers, and not much is known in terms of the optimal timing and type of activity. Moreover, the mechanism by which exercise impact on cancer risk and prognosis is largely unknown.

We recently took advantage of several murine tumor models to study the impact of exercise on cancer, and could demonstrate that voluntary exercise (wheel running) leads to a significant reduction in tumor size or incidence across the applied models [5]. Thus, exercise had a significant impact on tumor size in the transplanted Lewis lung cancer and B16 melanoma models—the latter studied both as subcutaneous (s.c.) tumors, as well as lung metastases...
established upon intravenous administration of cancer cells. Moreover, we could show an impact of exercise on tumor size and incidence on liver cancer using a diethylNitrosamine (DEN) induced liver cancer model, as well as the spontaneous melanoma model GrM1. To gain insight into the mechanism, we used the transplanted B16 melanoma model and compared tumors from exercise and control animals and, by microarray, showed that pathways associated with immune function were significantly up-regulated in tumors from exercise animals. Using real-time PCR, we validated the elevated expression levels of selected transcripts, and took advantage of immunohistochemistry (IHC) and flow cytometry, to substantiate these findings at the cellular level. Thus, tumors from exercise animals had a much denser infiltration of immune cells; T cells, B cells, dendritic cells, and NK cells. Since in particular NK cells were repeatedly increased in both subcutaneous and lung metastases of B16 tumors, we first used nude mice to see if exercise would still have an impact in the absence of T and B cells. Indeed, this was the case. As a next step, we went back to using B16 melanoma in wild type C57BL/6 mice, and used anti-asialo monoclonal antibody to clear NK cells from the animals. Strikingly, this completely abolished the effect of exercise, demonstrating that at least in the used transplanted tumor model, NK cells were necessary and sufficient for the effect [5]. NK cells are known to be capable of killing cancer cells [6], but a link between NK cells and the exercise associated anti-tumor response had not previously been scrutinized.

Exercise in humans is associated with a range of physiological changes, the magnitude of which is influenced by the intensity and duration of the exercise. Thus, there is an increase in cardiac output to meet oxygen demands, and a dramatic change in the pattern of blood flow. The metabolic rate goes up, and glucose consumption as well as output is increased, as is lactate levels due to anaerobic metabolism in muscle cells. Moreover, the endocrine system plays a key role in integrating the physiological responses both during rest and exercise [7]. To this end, catecholamines including epinephrine (adrenaline), and norepinephrine (noradrenaline) are significantly elevated during exercise through increased release from the adrenal glands. These hormones are part of the fight-or-flight response associated with increases in heart rate, blood pressure, blood glucose levels—and; immune function. To the latter, although there are conflicting data on the subject, there is consensus that acute exercise leads to a rapid increase in blood counts of various immune cells [7], followed by a drop to below baseline in turn followed by normalization of cell counts [8]. The most sensitive immune cell type to acute exercise is the NK cell [9], which are mobilized within minutes of exercise [10]. Maximal mobilization of NK cells is achieved after 30 min of exercise, and prolonged training does not lead to increased NK cell levels, but max level of NK cells can be maintained up to 3 h by continued training [9]. NK cells were initially characterized by being able to kill target cells without prior priming [6], and they normally function to clear virus infected, stressed, or transduced cells. This exercise-induced mobilization of NK cells is supposedly installed mainly by an increase in catecholamines. To this point, among leucocytes, NK cells express the highest levels of β-adrenergic receptors which is the receptor for catecholamines, especially norepinephrine and epinephrine [11], and the exercise associated mobilization of NK cells can be mimicked by administration of epinephrine [12].

In part based on the above, we first looked at serum levels of epinephrine and norepinephrine in exercise and control animals, and found that exercise animals had significantly higher amounts of both catecholamines. Moreover, we could block the effect of exercise on the increase in NK cell mobilization, immune cell influx to tumors, as well as impact on tumor progression by administration of the β-blocker propranolol [5]. Aiming at scrutinizing if epinephrine was alone responsible, we administered epinephrine to the animals, which did, indeed, impact on NK frequencies, immune cell infiltration into tumors, and size of tumors—but not as pronounced an effect as exercise. Thus, epinephrine is a key molecule in the exercise associated improved tumor control by cells of the immune system.

Since administration of epinephrine only partially mimicked exercise, we considered other molecules that could potentially play a role.

Exercise is associated with the release of myokines from the contracting muscles. One of the key myokines is interleukine-6 (IL-6) which is also known from its wide ranging and sometimes contrasting effects within the immune system. IL-6 is described to be pro-inflammatory in settings of bacterial infections and chronic inflammation, yet act anti-inflammatory by inhibiting TNF-α and IL-1, and activation of immune suppressive IL-10 [13]. During exercise, the plasma level of IL-6 increases rapidly in an intensity-dependent manner, through the release from exercise-engaged muscles [14]. As NK cells express the IL-6 receptor complex, we speculated whether exercise-mediated IL-6 release could play a role in, i.e., add to the effect of administration of epinephrine. We first cleared IL-6 using an IL-6 specific monoclonal antibody (mAb) which led to a diminished tumor control and also a less pronounced immune cell infiltration to the tumor; however, we could not mimic the role of IL-6 by administration of recombinant cytokine. Certainly, there could be many reasons for this; dosing, route of administration, timing related to levels of epinephrine, etc. At least one role IL-6 could play would be to increase mobilization of NK cells, since NK cells leaving the thymus were selectively expressing the IL-6α receptor. Cancer cells—including
melanomas—quite often express high levels of IL-6, which could, in turn, play a role in homing of NK cells expressing the IL-6 receptor. However, this is purely speculative and more work is needed to clarify the role of IL-6 in NK cell homing to the tumor site.

The data summarized above could have several important implications in humans both in relation to cancer incidence and therapy.

First, human NK cells express β-adrenergic receptors and as already mentioned administration of epinephrine leads to mobilization of NK cells. Similarly, bouts of acute exercise lead to mobilization of leucocytes most pronouncedly NK cells, and thus, increase in systemic NK cell frequencies is a key immunological feature of exercise in man as well as mouse [15]. It should be mentioned, however, that in all sc. B16 tumors from exercise mice, we also saw increased numbers of T cells. T cells also express β-adrenergic receptors and are thus also mobilized by epinephrine. Moreover, killing of cancer cells by NK cells may have led to uptake of tumor antigen by dendritic cells, and induction of tumor-specific T-cell responses. In terms of the function of NK cells, although different in terms of cell surface markers and signalling molecules [16], there are basic similarities in terms of being similarly capable of recognizing and killing of cancer cells as a functional response to recognizing “missing self” [6]. NK cells may also recognize cancer cells by activating receptors, e.g., NKG2D recognizing ligands expressed on cancer cells [17]. Thus, exercise in humans mobilizes NK cells, and human NK cells are efficient cancer cell killers—and, therefore, could play a protective or therapeutic role in cancer. To this end, Moore and colleagues recently pooled data from 12 prospective cohorts with self-reported physical activity for association with incidence of 26 types of cancer, and could demonstrate that leisure-time physical activity is significantly associated with a lower risk of cancer, e.g., cancers of the oesophagus, liver, lung, kidney, colon, breast, and as well as leukemia and myeloma [2]. Strikingly, two cancers showed physical activity associated with higher risk of cancer, melanoma, and prostate cancer. For melanoma, this could supposedly be due to sun exposure during exercise. For advanced prostate cancer, there was no relationship between physical activity and cancer, suggesting that men that exercise, are more prone to be examined and diagnosed—in some cases with indolent prostate cancer. Nonetheless, with two exceptions, physical activity is associated with lower risks of a range of cancer types. Obviously, these data do not by itself reveal insight into the molecular or cellular background but underscore that the exercise associated immune mobilization could potentially play a role in cancer prevention. To this end, a key feature of the protective role of exercise in our mouse studies was an increased number of immune cells in tumors from exercise animals [5], a feature known to be associated with longer survival in humans [18]. Moreover, immune infiltration can be studied in humans by serial biopsies before and after exercise. Thorough studies of the composition of immune cells infiltrating the tumor could possibly reveal data to support the notion of improved immunological control of tumor progression, and set the stage for combination treatment as given in more detail below.

Second, in our fast growing transplantable B16 melanoma model, NK cells were responsible for the anti-cancer effect of exercise, and NK cells had significant effect in the absence of T and B cells. As a consequence, it is possible that fast growing transplantable models in which NK cells do not play a substantial role would see limited or no effect of exercise. In our B16 model, the most pronounced effect was achieved when exercise was initiated prior to inoculation of cancer cells. We also did studies in which exercise was initiated concurrent with cancer cell inoculation and saw only a trend towards smaller tumors in the exercise group [5]. Hence, it makes sense to speculate that prior exercise implies that more NK cells are in circulation and ready to home to the inoculation site and kill cancer cells immediately at the site of injection. Thus, we have no evidence that NK cells alone are responsible for the effect using more clinically relevant tumor models. In more slowly developing tumor models, e.g., the DEN or the GrM1 model, we are currently following the hypothesis that NK cells are key cells in delivering the “spark” that could be a main denominator for setting the stage for induction of a full scale response involving all appropriate cell types necessary for an anti-cancer immune attack: most importantly dendritic cells and T cells. This would be in line with the data suggesting NK cells to play a main role in very early phases of tumorigenesis and a less pronounced role once the tumor is established [18, 19]. This notion is supported by the fact that solid tumors comprise quite few NK cells, whereas infiltrates of T cells are often present in more substantial numbers [20]. A key role of NK cells in protection rather than therapy is also suggested from a study in which NK cell levels were studied longitudinally with an 11 year interval using a functional cytotoxicity readout, which showed that a high level of cytotoxic activity among peripheral blood lymphocytes was associated with a lower risk of cancer [21]. Again, this suggests NK cells as active in early tumor surveillance.

In terms of translation to a human setting, maybe, the most important finding of our recent study is the impact on exercise shown using the chemically induced model (DEN) or the spontaneous melanoma model. In the DEN model, we saw a decreased in tumor incidence going from 70 to 30%, and given the fact that the immune infiltrate in B16 showed a significant increase not only in NK cells, but also dendritic cells, B cells, and T cells, we hypothesize that
in the slow growing more clinically relevant models, NK cells may be involved with early surveillance, while other immune subsets play a more important role in anti-tumor responses against the established tumor. Third, given the immune cell mobilizing and tumor infiltrating effect of exercise, this could potentially play a role as combination or conditioning partner to immune therapy. To this end, the immune check point inhibitory mAb are now approved in several cancers and the list of cancer indications is certain to increase. In particular, blockade of the PD-1 axis by mAbs seems to induce clinical responses by unleash of spontaneous tumor-specific immune responses at the tumor site [22]. Importantly, data are accumulating to suggest that patients whose tumors are characterized by a brisk infiltration of immune cells are more prone to respond to treatment [23]. As consequence, huge research efforts are undertaken to scrutinize methods by which tumors with limited or absent immune cell infiltrates, i.e., “cold tumors” can be turned into “hot” tumors with a brisk infiltration of anti-tumor immune cells, T cells, NK cells, dendritic cells, etc. Therefore, exercise prior to PD-1 therapy could represent a tool that condition patients to immunotherapy by increasing the immune infiltrate in the tumor, and in turn increase the chance for clinical response. Adoptive cell transfer (ACT) using tumor infiltrating lymphocytes (TIL) represents another breakthrough in immunotherapy of cancer. A very obvious requirement for clinical success is the presence of tumor-specific T cells in the tumors, since these cells prepare the platform for expansion in vitro and administration of high numbers of tumor-specific T cells back to the patient. In melanoma patients, 50% of patients respond to treatment with an impressive 20% experiencing lasting complete, i.e., supposedly curative responses [24, 25]. As mentioned, exercise prior to surgery for harvest of T cells could possibly promote the quantity of cells and maybe also the quality of “new” immune cells in tumor. Prior to clinical testing, this could be studied by harvesting of serial biopsies for studies of immune cell infiltration and in vitro functionality of immune cells, in the pre-clinical and clinical setting, by studying needle biopsies before and after monitored exercise programs. Several lines of evidence point at the immune system as being crucial also for the efficacy of chemotherapy [26]. If substantiated by human studies, exercise could play a role by improving also response to the conventional treatments [27].

Cancer immunotherapy is now clinically validated in many cancers, and even in very late stage patients, lasting complete responses are not uncommon. However, for most treatments, the majority of patients do not respond and predictive markers are missing. Hence, there is an urgent call for characterization of predictive markers and tools to increase response to therapy. To the latter, exercise is known to be healthy in an array of aspects in the life of modern human beings. Based on our data in mouse models, we suggest that exercise could represent a suitable combination partner to immune therapy in cancer patients, facilitating improved response rates and more frequent complete lasting responses. Moreover, exercise may directly—as a key component of a healthy lifestyle—delay or prevent tumor development.

Acknowledgements The study was supported by grants from The Danish Cancer Society, The Danielsen Foundation, The Toyota Foundation, Dagmar Marshalls Foundation, and Ericksens Memorial Fund.

Compliance with ethical standards

Conflict of interest The authors have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Kujala UM, Kaprio J, Sarna S, Koskenvuo M (1998) Relationship of leisure-time physical activity and mortality: the Finnish twin cohort. JAMA 279:440–444
2. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, Keadle SK, Arem H, Berrington de GA, Hartge P, Adami HO, Blair CK, Borch KB, Boyd E, Check DP, Fournier A, Freedman ND, Gunter M, Johannson M, Khaw KT, Linet MS, Orsini N, Park Y, Riboli E, Robien K, Schairer C, Sesso H, Siprigs M, Van DR, Wolk A, Matthews CE, Patel AV (2016) Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med 176:816–825
3. McTiernan A (2008) Mechanisms linking physical activity with cancer. Nat Rev Cancer 8:205–211
4. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM (2012) Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 104:815–840
5. Pedersen L, Idorn M, Olofsson GH, Nookaew I, Hvass Hansen R, Hjort Johannesen H, Becker JC, Lauenborg B, Pedersen KS, Dethlefsen C, Nielsen J, Gehl J, Pedersen BK, thor Straten P, Hojman P (2016) Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab 23:554–562
6. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675–678
7. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleschner M, Green C, Pedersen BK, Hoffman-Goetz L, Rogers CJ, Northhoff H, Abbasi A, Simon P (2011) Position statement. Part one: immune function and exercise. Exerc Immunol Rev 17:6–63
8. Gleeson M, Bishop NC (2005) The T cell and NK cell immune response to exercise. Ann Transplant 10:43–48

© Springer
9. Timmons BW, Cieslak T (2008) Human natural killer cell subsets and acute exercise: a brief review. Exerc Immunol Rev 14:8–23
10. Shephard RJ, Shek PN (1999) Effects of exercise and training on natural killer cell counts and cytolytic activity: a meta-analysis. Sports Med 28:177–195
11. Dimitrov S, Lange T, Born J (2010) Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol 184:503–511
12. Schedlowski M, Hosch W, Oberbeck R, Benschop RJ, Jacobs R, Raab HR, Schmidt RE (1996) Catecholamines modulate human NK cell circulation and function via spleen-independent beta-2-adrenergic mechanisms. J Immunol 156:93–99
13. Cullen T, Thomas AW, Webb R, Hughes MG (2016) Interleukin-6 and associated cytokine responses to an acute bout of high-intensity interval exercise: the effect of exercise intensity and volume. Appl Physiol Nutr Metab 41:803–808
14. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK (2002) IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272–E1278
15. Bigley AB, Rezvani K, Chew C, Sekine T, Pistillo M, Crucian B, Bollard CM, Simpson RJ (2014) Acute exercise preferentially redeployes NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain Behav Immun 39:160–171
16. Cerwenka A, Lanier LL (2016) Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol 16:112–123
17. Lanier LL (2015) NKG2D receptor and its ligands in host defense. Cancer Immunol Res 3:575–582
18. Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC, Sautes-Fridman C (2014) The immune microenvironment: a major player in human cancers. Int Arch Allergy Immunol 164:13–26
19. Guillerey C, Smyth MJ (2015) NK cells and cancer immunoediting. Curr Top Microbiol Immunol 341:37–58
20. Stojanovic A, Correia MP, Cerwenka A (2013) Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron 6:135–146
21. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356:1795–1799
22. Shin DS, Ribas A (2015) The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol 33:23–35
23. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF (2014) Mechanism of tumor rejection with doublet of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2:14
24. Andersen R, Donia M, Ellebaek E, Holz Borch T, Kongsted P, Iversen TZ, Rosenkrantz Hölmich L, Westergren Hendel H, Met O, Andersen MH, thor Straten P, Svane IM (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin Cancer Res 22:3734–3745
25. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550–4557
26. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, Van EP, Ciccosanti F, Picentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61
27. Sistigu A, Yamarzaki T, Vacchelli E, Chaba K, Enot DP, Adam I, Vitale I, Goubar A, Baracco EE, Remedios C, Fend L, Hanan D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tueting T, Belardelli F, Bracci L, La S, V, Zicheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidvilde V, Conforti R, Spano JP, Putzta L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnold L, Cyrtja L, Des Hollers MC, Eggermont A, Bianchi ME, Pitett M, Engblom C, Pitrischke C, Preville X, Uze G, Schreiber RD, Chow MT, Smyth MJ, Piotto E, Andre F, Kroemer G, Zitvogel L (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20:1301–1309